

Crocin synergistically enhances the anti-proliferative activity of 5-FU through Wnt/PI3K pathway in a mouse model of colitis-associated colorectal cancer

Article (Accepted Version)

Amerizadeh, Forouzan, Rezaei, Nastaran, Rahmani, Farzad, Hassanian, Seyed Mahdi, Moradi-Marjaneh, Reyhaneh, Fiuji, Hamid, Boroumand, Nadia, Nosrati-Tirkani, Abolfazl, Ghayour-Mobarhan, Majid, Ferns, Gordon A, Khazaei, Majid and Avan, Amir (2018) Crocin synergistically enhances the anti-proliferative activity of 5-FU through Wnt/PI3K pathway in a mouse model of colitis-associated colorectal cancer. *Journal of Cellular Biochemistry*, 119 (12). pp. 10250-10261. ISSN 0730-2312

This version is available from Sussex Research Online: <http://sro.sussex.ac.uk/id/eprint/77287/>

This document is made available in accordance with publisher policies and may differ from the published version or from the version of record. If you wish to cite this item you are advised to consult the publisher's version. Please see the URL above for details on accessing the published version.

Copyright and reuse:

Sussex Research Online is a digital repository of the research output of the University.

Copyright and all moral rights to the version of the paper presented here belong to the individual author(s) and/or other copyright owners. To the extent reasonable and practicable, the material made available in SRO has been checked for eligibility before being made available.

Copies of full text items generally can be reproduced, displayed or performed and given to third parties in any format or medium for personal research or study, educational, or not-for-profit purposes without prior permission or charge, provided that the authors, title and full bibliographic details are credited, a hyperlink and/or URL is given for the original metadata page and the content is not changed in any way.

Crocin Synergistically enhances the anti-proliferative activity of 5-FU through Wnt/PI3K pathway in a mouse model of colitis-associated colorectal cancer

Forouzan Amerizadeh^{1,2,*}, Nastaran Rezaei^{3,*}, Farzad Rahmani^{4,5*}, Seyed Mahdi Hassanian^{1,4,*}, Reyhaneh Moradi-Marjaneh^{3,6}, Hamid Fiuji¹, Nadia Boroumand⁴, Abolfazl Nosrati-Tirkani¹, Majid Ghayour-Mobarhan¹, Gordon A. Ferns⁷, Majid Khazaei^{1,3,#}, Amir Avan^{1,2,8#}

Affiliations:

- 1) *Metabolic syndrome Research center, Mashhad University of Medical Sciences, Mashhad, Iran.*
- 2) *Department of Modern Sciences and Technologies, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.*
- 3) *Department of Physiology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.*
- 4) *Department of Medical Biochemistry, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.*
- 5) *Student Research Committee, Mashhad University of Medical Sciences, Mashhad, Iran.*
- 6) *Torbat Heydariyeh University of Medical Sciences, Torbat Heydariyeh, Iran*
- 7) *Brighton & Sussex Medical School, Division of Medical Education, Falmer, Brighton, Sussex BN1 9PH, UK.*
- 8) *Cancer Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.*

Running title: Crocin/5-FU combination in colorectal cancer

Corresponding Authors:

Majid Khazaei MD PhD, Department of Physiology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
Tell: +98 513 8002227; E-mail: Khazaeim@mums.ac.ir

Amir Avan, Ph.D. Metabolic syndrome Research center, Mashhad University of Medical Sciences, Mashhad, Iran Tell: +98 513 8002298; E-mail: avana@mums.ac.ir

Source of Funding

This research was partly supported by grants awarded by the Mashhad University of Medical Sciences, grant No. 960692 (Amir Avan), grant No: 961206 of the Biotechnology Development Council of the Islamic Republic of Iran and TWAS-UNESCO No. 17-094 RG/PHA/AS_C – FR3240300063.

* Equally contributed as first author

Disclosures: The authors have no conflicts of interest to declare.

Abstract

Colorectal-cancer (CRC) is the third most common cause of cancer-related-death, and hence there is a need for the identification of novel-agents to improve the efficacy of existing-therapies. There is growing evidence for the anti-tumor-activity of crocin, although its activity and molecular-mechanisms in CRC remains to be elucidated. Here we explored the therapeutic-application of crocin or its combination with 5-Flurouracil in a mouse-model of colitis-associated colon-cancer. The anti-proliferative-activity of crocin was assessed in 2- and 3-dimensional cell-culture-models. The migratory-behaviors were determined, while the expression-levels of several-genes were assessed by qRT-PCR/Western-blotting. We examined the anti-inflammatory properties of crocin by pathological-evaluation and disease-activity-index as well as oxidative/ antioxidant markers: malondialdehyde (MDA) and total-thiols (T-SH) levels and superoxide-dismutase (SOD) and catalase (CAT) activity. Crocin suppressed cell-growth and the invasive-behavior of CRC-cells through modulation of the Wnt-pathway and E-cadherin. Moreover, administration of crocin alone, or in combination with 5-FU dramatically reduced the tumor-number and tumor-size in both distal/mid-colon followed by reduction in disease-activity-index. Crocin also suppressed the colonic-inflammation induced by Dextran-sulfate-sodium and notably recovered the increased-levels of MDA, decreased Thiol-levels and activity of CAT-levels. Crocin was able to ameliorate the severe-inflammation with mucosal-ulcers and high grade-dysplastic-crypts as detected by inflammation-score, Crypt-loss, pathological-changes and histology-scores. We demonstrated an antitumor-activity of crocin in CRC and its potential role in improvement of inflammation with mucosal ulcers and high grade dysplastic crypts, supporting the desirability of further investigations on the therapeutic potential of this approach in CRC.

Keywords: colorectal cancer; crocin; anti-tumor effect; colitis-associated colorectal cancer gastrointestinal

Introduction

Colorectal cancer (CRC) remains the third most common type of malignancy globally (Siegel, Miller & Jemal, 2016). Recently, both clinical and basic science studies have made considerable progress in the therapeutic strategies used in CRC; these currently include surgery, radiotherapy and, most notably chemotherapy. However, the overall survival rate of patients with CRC remains disappointing due to: drug-resistance, severe side effects and high recurrence rate (Longley, Allen & Johnston, 2006). 5-fluorouracil (5-FU) treatment, alone or in combination with other chemical cytotoxic drugs, is among the routinely used standard therapies in CRC (Bahrami et al., 2017b; Bahrami et al., 2017c; Bahrami et al., 2017d; Hammond, Swaika & Mody, 2016). Despite its therapeutic benefits, 5-FU has also shown limited efficacy, high resistance, and a low response rate in advanced CRC patients (Bahrami et al., 2017a; Zhang, Yin, Xu & Chen, 2008). These limitations have necessitated further research for developing more efficient alternative or potential combinational agents in chemopreventive and chemotherapeutic strategies in order to enhance effectiveness, while reducing toxicity and resistance.

Recently, crocin has emerged as a novel anti-cancer agent in the treatment of several tumor types, including hepatic, pancreatic, prostate, breast, and colorectal cancers (Amin et al., 2016; Aung et al., 2007; Chryssanthi, Dedes, Karamanos, Cordopatis & Lamari, 2011; D'Alessandro et al., 2013; Dhar et al., 2009). There are already studies showing the therapeutic value of crocin as anti-convulsant, anti-inflammatory, anti-depressant and anti-tumor molecule (Hosseinzadeh, 2014). Hoshyar et al. showed that crocin could induce apoptosis in gastric adenocarcinoma cells via increasing Bax/Bcl-2 ratio in stimulated cells (Hoshyar, Bathaie & Sadeghizadeh, 2013). Bathaie et al. explored the beneficial activity of saffron extract on gastric cancer in an *in vivo* experiment. They showed that an aqueous extract of saffron, inhibited the progression of cancer in rats dose dependently in gastric cancer (Bathaie, Hoshyar, Miri &

Sadeghizadeh, 2013; Bathaie, Miri, Mohagheghi, Mokhtari-Dizaji, Shahbazfar & Hasanzadeh, 2013). Moreover, a study in diethylnitrosamine-treated rats showed that saffron potently inhibited nodular and foci of altered hepatocyte formation in the rat liver. The authors found that this inhibition was correlated with induced apoptosis, decreased cell proliferation, reduced oxidative stress and down-regulation of some inflammatory markers including NF- κ B (nuclear factor kappa-light-chain-enhancer of activated B cells), Inducible nitric oxide synthase (iNOS) and COX-2 (Amin, Hamza, Bajbouj, Ashraf & Daoud, 2011). Furthermore, Aung et al. reported that crocus sativus extract and crocin possess remarkable anti-proliferative effects on CRC cells (Aung et al., 2007). Similarly, it has been shown that long-term treatment with crocin elevated survival rate in rats with CRC (Garcia-Olmo et al., 1999).

In this current study, we assessed the anti-tumor activity of crocin alone to investigate its potential as a chemotherapeutic compound, and also in combination with 5-FU to explore whether crocin treatment could improve the anti-tumor activity of 5-FU both in *in vitro* and in colon cancer mice models. Moreover, we investigated the anti-oxidant activity of crocin. Next, to investigate the underlying molecular changes within anti-cancer activity of crocin, alone and in combination with 5-FU, we evaluated the expression of related specific key molecular markers in monolayer and three-dimensional cultured cells to imitate the tumor microenvironment.

Methods and materials:

Drugs and chemicals:

Crocin was obtained from Faculty of Pharmacy, Mashhad University of Medical Sciences (Mashhad, Iran). 5-FU was purchased from MUMS and dissolved in ethanol or sterile water. Dulbecco's Modified Eagle Medium (DMEM), fetal bovine serum (FBS), penicillin (50 IU/ml) and streptomycin (50 μ g/ml) were purchased from Gibco (Gaithersburg, MD). Azoxymethane (AOM), and dextran sodium sulfate (DSS; MW=40 kD) were purchased from Sigma Chemical Co. (St. Louis, MO, USA).

Cell culture:

CT-26 cell line was originally purchased from Pasteur institute, Tehran, Iran. The cells were grown in DMEM containing 10% heat-inactivated FBS and 1% streptomycin/penicillin. The cells were maintained at 37 °C in 5% CO₂ atmosphere. Regular passaging was performed in their exponentially growing phase, at 70%–80% confluency, by using trypsin-EDTA (Rovithi et al., 2017).

Growth inhibition studies:

The cell growth inhibitory effects of crocin, 5-FU, and their combination were evaluated by the MTT assay before and after 24-72 hour-treatment. CT-26 cells were treated for 24 hours with crocin (1-500 μ M), 5-FU (1-500 nM), and simultaneous combination at a fixed ratio based on IC₅₀ (i.e. concentration of a drug required for 50% inhibition of cell growth) of each drug. The plates were then processed for MTT as described previously (Avan et al., 2013b).

Evaluation of synergistic/antagonistic interaction with 5-FU:

The pharmacological interaction between crocin and 5-FU was evaluated by the median drug effect analysis method as described previously (Maftouh et al., 2014b). Briefly, the combination index (CI) was calculated to compare cell growth inhibition of the combination and each drug alone. Data analysis was carried out using CalcuSyn software (Biosoft, Oxford, UK).

Multicellular spheroids:

The spheroids were formed by seeding 10⁵ cells per ml in DMEM/F12+GlutaMAX-I (1:1) in agarose coated 96-well plates. The cell attachment, growth and cytotoxic effects were determined for 10 days under the inverted phase contrast microscope Leica-DMI300B (Leica, Wetzlar, Germany). Spheroid volume (V) was defined from the geometric mean of the

perpendicular diameters $D = (D_{\max} + D_{\min})/2$, as follows: $V = (4/3) \times \pi (D/2)^3$ (Maftouh et al., 2014c).

In vitro invasion assay:

Cell invasion assays were carried out using trans-well chambers with polycarbonate membranes and 8- μ m pores (Maftouh et al., 2014b; Nedaeinia et al., 2016). The trans-well filters were coated with 100 μ l of 0.1 mg/mL collagen I solution. Briefly, 10^5 cells were plated on the upper face of the filter and incubated with crocin at 2 mM in serum free media. Migratory cells attached to the polycarbonate membranes were fixed with paraformaldehyde solution for 24 hours. The filters were then photographed and counted after visualization with Giemsa stain.

Migration assays

The ability of crocin and its combination with 5-FU to inhibit the migratory behavior of CT-26 cells was investigated by in vitro migration assay, as described previously (Giovannetti et al., 2014). The cells were exposed to the drug at their 2 mM. Images were taken at the beginning of the exposure (time 2), with those taken after 7, 11, 13, 23, 32 hours.

Quantitative Reverse-Transcriptase Polymerase-Chain-Reaction (qRT-PCR):

Total RNAs were extracted from the cells before and after treatment with crocin at IC_{50} (3mM) and using the RNXPLoS (CinaColon, Tehran, Iran), according to the manufacturer's protocol. cDNA was synthesized by cDNA Synthesis Kit (CinaColon, Tehran, Iran). Quantitative RT-PCR was performed with specific primers for CyclinD1, survivin, MMP-2, MMP-9, and E-cadherin (Macrogen co, Seoul, Korea). The cDNA was amplified by ABI-PRISM StepOne instrument (Applied Biosystems, Foster City, CA). Gene expression data were normalized to GAPDH,

using a standard curve of cDNAs purchased from Quantitative PCR Human Reference RNA (Stratagene, La Jolla, CA), as described (Maftouh et al., 2014a)(Peters et al., 2014).

Cell cycle assay

To further investigate the anti-proliferative effect of crocin on cell cycle progression, CT-26 cells were treated with two concentrations of crocin (3mM, 5mM) for 24 hours and were analyzed using flow cytometry, as described previously (Giovannetti et al., 2014)(Marjaneh et al., 2018). The effect of drugs on modulation of cell cycle was assessed in the cells treated for 24 hours with two concentrations of crocin at IC₅₀ concentrations. Cells were stained by propidium iodide (PI) and cell cycle modulation was determined using a FACSCalibur flow cytometer (Becton Dickinson, San José, CA), equipped with the CELLQuest software for data analysis. The ability of crocin and its combination with 5-fu to induce cell death was explored by measuring sub-G1 regions during cell cycle analysis, as described previously.

Western blot analysis:

Western blot analyses were performed as described previously (Anto, Mukhopadhyay, Denning & Aggarwal, 2002). Briefly, 40 µg of proteins were separated on a 10% SDS-polyacrylamide gel and transferred onto PVDF membrane (Immobilion®-FL, Millipore, Billerica, MA). The membrane was incubated overnight with rabbit anti-CyclinD1 (Santa Cruz Biotechnology, Santa Cruz, CA), anti-PI3K, anti-p-Akt, and anti-p-GSK3α/β (Abcam, Cambridge, UK), and anti-β-actin (1:10000; Sigma–Aldrich). The secondary antibody was goat anti-rabbit (1:10000, Westburg, Leusden, The Netherlands). The membrane was then proceeded for visualization via chemiluminescence detection (Avan et al., 2013a; Avan et al., 2012).

Animal experiment:

The animal experiments were approved by Ethical Committee of animal experiment of the Mashhad University of Medical Science. Eightweek old female C57BL/6 mice were supplied by Pasteur Institute (Tehran, Iran) and divided into 4 groups (n=6 each): control, treated with 5-FU, or crocin, or a 5-FU/crocin combination. Mice were given a single intraperitoneal injection of AOM (10 mg/kg body weight followed by three cycles of 1.5% DSS in drinking water for 1 week and normal drinking water for 2 weeks (Kawabata, Tung, Shoyama, Sugie, Mori & Tanaka, 2012). Starting one week after the second DSS exposure, groups 3, 4, and 5 received diets containing crocin (200 ppm in drinking water), 5-FU (35 mg/kg once weekly (Almagami, Alshawsh, Saif-Ali, Shwter, Salem & Abdulla, 2014) and crocin + 5-FU, respectively. Group 1 was served as an untreated control. All animals were sacrificed at week 10. For macroscopic and histological examination of tumors, the colons were isolated and washed by ice-cold phosphate-buffered saline (PBS) and opened longitudinally and assessed tumor number and tumor size with digital caliper. Tumor localization was also determined. Then, distal colon samples were placed into 10% formalin solution for histopathological examination. The histopathological examination was conducted on paraffin-embedded 5 µm sections which were stained with hematoxylin and eosin (H&E). The middle parts of colons were stored at -70°C for evaluation of oxidative/ antioxidative markers. For this purpose, colonic tissues were homogenized on ice in tissue-lysis buffer. Homogenates were then centrifuged at 4°C for 1 h at 10000 rpm, and the supernatants were used for oxidative/ antioxidative markers.

Scoring Inflammation

The inflammation was scored in the large bowel. Large intestinal inflammation was graded with respect to the morphological criteria (Sugie, Suzuki, Tanaka & Kohno, 2005) as following: normal appearance (grade 0); shortening and loss of the basal 1/3 of the actual crypts together with mild inflammation in the mucosa (grade 1); loss of the basal 2/3 of the crypts and moderate

inflammation in the mucosa (grade 2); loss of all of the crypts plus severe inflammation in the mucosa and sub-mucosa, while the surface epithelium retained (grade 3); the mucosal ulcer presentation with severe inflammation in the mucosa, sub-mucosa, muscularis propria, and/or subserosa (grade 4). The scoring was carried out on the entire colon with/without proliferative lesions and was considered as a mean score/mouse (Hashemzahi et al., 2018).

Measurement of malondialdehyde (MDA)

MDA level is a marker of lipid peroxidation and was used to evaluate the antioxidant activity of crocin. Shortly, 1 ml of 10% homogenates mixed with 2 mL of TBA + TCA + HCL solution for 45 minutes in a boiling water bath and centrifuged for 10 minutes. Then, the absorbance at 535 nm was read and MDA was calculated by $C (M) = A / 1.65 \times 10^5$ (Hashemzahi et al., 2018).

Measurement of total thiol groups (SH)

Total thiol was measured using DTNB (Di-Tio nitro benzoic acid) reagent. 1ml of Tris-EDTA buffer (pH = 8.6) was added to tissue homogenate. The specimen absorbance read at 412 nm against Tris-EDTA buffer alone (A1). Then 20 µl of DTNB reagents were added to this solution and stored for 15 minutes at room temperature. Then, the sample absorbance was record again (A2). The absorbance of DTNB reagent was record lonely as a blank (B). Total thiol concentration (mM) was calculated from the following formula (Total thiol concentration (mM) = $(A2-A1-B) \times 1.07 / 0.05 \times 13.6$) (Hosseinzadeh & Sadeghnia, 2005).

Measurement of superoxide dismutase (SOD) and catalase (CAT) activity

SOD was assessed by Ransod kit (Randox Laboratory, UK), while CAT activity was evaluated as described by Aebi et al (Aebi, 1984). The principle of this method was based on the hydrolyzation of H_2O_2 in phosphate buffer, pH 7.0, and essential volume of sample and reducing

absorbance at 240 nm. Enzyme response velocity can be measured by the conversion of H_2O_2 to H_2O and O_2 in 1min below standard condition (Hashemzahi et al., 2018).

Statistical analysis:

All experiments were performed in triplicate and repeated at least twice. Data were expressed as mean values \pm SEM and analyzed by Student's t-test or ANOVA followed by Tukey's multiple comparison test. Data were analyzed by SPSS v.20 statistical software (IBM, Chicago). Statistical significance was set at $P < 0.05$ (Avan et al., 2014)(Oladi et al., 2015; Avan et al., 2013).

Result

Crocin inhibits colon cancer cell growth in monolayer cell culture

To investigate the anti-proliferative activity of crocin alone and its combination with 5-FU, CT26 cells were exposed to increasing concentrations of crocin (1nM–10mM) and 5-FU (1–50 mg/ml) for 24 hr. This analysis showed that crocin and 5-FU inhibited cell growth in a dose-dependent manner (Fig. 1A). Results clearly showed that co-treatment of crocin and 5-FU decreased the IC_{50} value of 5-FU. The median drug effect analysis, comparing cell growth inhibition of the combination and each drug alone revealed a slight synergism between crocin and 5-FU (Fig.1B).

Crocin causes tumor shrinkage in CT-26 cells

To further assess whether crocin could be active in three-dimensional models of cell culture and overcome the major obstacles in conventional cell culture method, CT-26 spheroids were developed and treated with crocin at IC_{50} (3 mM) and $5 \times \text{IC}_{50}$ values. Tumor shrinkage was detected after 8 days as shown in Figure 1C.

Crocin and its combination with 5-FU inhibit invasive behavior of CRC cells

The effect of crocin on cell invasion was explored by the invasion assay in the cells treated with crocin at IC_{50} (3 mM) and $5 \times IC_{50}$ values. Our data showed that the invasion of CT-26 cells, treated with crocin and 5-FU in combination, was significantly reduced as compared with control group (Fig. 1D). To further investigate the mechanism of the inhibitory effect of crocin on CRC invasive behavior, expression of E-cadherin, a cell adhesion molecule, was analyzed in the presence and absence of crocin in these cells. Results showed that crocin significantly increased expression of E-cadherin in crocin-stimulated cells (Fig.1E).

Crocin and its combination with 5FU inhibited the migratory behavior of colorectal cancer cells

To investigate the effects of crocin on migratory behavior, a scratch mobility assay was carried out in CT26 cells (Fig. 1F). The cells were exposed to crocin in IC_{50} concentration (3mM) and they showed a significant reduction of migration starting after 20 hours exposure to crocin compared to control.

To further confirm the anti-metastatic behavior of the cells treated with crocin, we evaluated the expression of matrix metalloprotease-2 and -9 (MMP-2 and MMP-9), two gelatinases which facilitate cell invasion by breaking down the extracellular matrix (Said, Raufman & Xie, 2014). As shown in figure 1E, crocin significantly suppressed the expression of MMP-2 and MMP-9 suggesting the mechanism by which crocin decreased cellular migration and metastasis in CRC cells.

Crocin suppresses cell cycle progression in CRC cells.

To further explore the regulatory effect of crocin on cell cycle progression, CT-26 cells were treated with two concentrations of crocin (3 mM and 5 mM) for 24 hours and were analyzed by

flowcytometry method. Our results indicated that crocin significantly increased the percentage of sub G1 population in dose dependent manner (Fig 2 A-D). As shown in Figure 2, when cells were treated with crocin (3 mM), the percentage of Sub-G1 population showed a marked increase (23.1%) compared with the control group (1.1%). These data suggest that crocin induces CRC cell apoptosis by arresting cells in G0/G1 phase of cell cycle.

Crocin suppresses tumor growth in a mouse model of colitis-associated colorectal cancer

We first develop colitis-associated colorectal cancer models, as the workflow outlined in Fig 3A. Mice were given 10 mg/kg body weight AOM. One week after AOM injection, they received 1.5% DSS/oral-gavage for 7 days, followed by 2 weeks rest. One week after DSS exposure groups 3, 4, and 5 were treated with crocin, 5-FU, crocin and 5-FU for 15 weeks, respectively. The possible physiological significance of anti-proliferative effect of crocin was demonstrated by findings that crocin potently decreased CRC growth in animal model too. As shown in Fig.3 B, the tumor numbers were significantly reduced in crocin and 5-FU groups. Interestingly this reduction was much higher in combination group (Fig.3B). Similar results were also observed for tumor size and tumor number based on the location with respect to the colon area and we observed treatments had more impact on larger tumor (more than 2 mm in diameter.(Fig. 3C-D). Moreover, our data showed that tumor area with respect to the colon length was markedly decreased in combination group, compared to crocin or 5-FU groups or control group (Fig. 3E). Also crocin was able to improve the colon length, compared to control mice which they didn't received therapy (Fig 3 F-G).

Crocin affects MDA, thiol and CAT activities

To determine the role of crocin on oxidative stress, the levels of SOD, CAT and MDA and thiol were analyzed in homogenized colon samples and results presented in Fig. 4 A-D. In particular

the level of MDA and CAT were significantly increased and decreased, respectively, in mice only treated with AOM and/or DSS (group 2).(Figure 4A-B). Our data showed that mice treated with crocin or its combination with 5-FU was able to reduce the level of MDA, while increasing the CAT or thiol activities, suggesting that crocin attenuates inflammatory responses by regulating oxidative stress in tumors.

Crocin ameliorates multiplicity of severe inflammation with mucosal ulcers and high grade dysplastic crypts

The H&E staining of resected tumors revealed an organized structure of tumor cells nests within stromal tissue. These tumors also showed the presence of Polypoid well-differentiated adenocarcinoma and pedunculated adenocarcinoma with invasion to muscular layer. Also AOM and/or DSS treatment resulted in the occurrence of veracious colorectal lesions, such as colitis with mucosal ulcers, dysplastic crypts, tubular adenoma, and tubular adenocarcinoma. The incidences and multiplicity of severe colorectal inflammation with mucosal ulcers, the inflammation score, and the presence of dysplasia are shown in Figure 5A-C. In particular our data showed that the total score of inflammation, crypt loss, pathological changes and histology score of mice treated with crocin were significantly reduced and improved, compared to control group (Fig. 5 D-J). Moreover, crocin was able to ameliorate multiplicity of severe inflammation with mucosal ulcers and high grade dysplastic crypts as detected by total score of inflammation, Crypt loss, pathological changes and histology scores (Fig. 5G-N).

Crocin suppresses PI3K/Akt and Wnt/b-catenin pathways in colorectal cancer

To further investigate the molecular mechanisms of anti-proliferative activity of crocin, the effects of this pharmacologically active component on PI3K/Akt and Wnt/b-catenin signaling pathways were analyzed. It has been reported that PI3K/Akt signaling pathway regulated

several downstream signaling pathways involved in cellular proliferation, survival and apoptosis (Michl & Downward, 2005). Thus, we examined the inhibitory effect of crocin on protein levels of PI3K, cyclin D1 and phosphorylated levels of Akt and glycogen synthase kinase 3 α / β (GSK-3 α / β) by western blot method. Several studies indicated that the oncogenic PI3K/Akt signaling induces Wnt/ β -catenin signaling by phosphorylation and inactivation of GSK-3 α / β . GSK-3 α / β is the key negative regulator of Wnt signaling pathway which is suppressed upon phosphorylation and then the activated pathway increases expression of its down-stream targets including cyclin D1. Cyclin D1 is one of the Wnt/ β -catenin targets genes, mainly involved in regulation of the G1 to S phase in the cell cycle (Vadlakonda, Pasupuleti & Reddanna, 2013). Our results showed that crocin inhibited expression of PI3K and its downstream targets like cyclin D1 and survivin in CRC cells in a concentration-dependent manner (Fig. 6 A&C). We also showed that crocin suppressed phosphorylation of Akt and GSK 3 α / β (Fig. 6C), suggesting that the anti-proliferative function of crocin is at least partially mediated by attenuating Wnt/PI3K signaling pathway activation in crocin-stimulated cells.

Discussion

To the best of our knowledge this is the first study evaluating the combination of crocin and 5-FU in 2- and 3-dimensional cell culture models of CRC cells as well as in a mouse model of colitis-associated colon cancer. Our results showed that crocin synergistically enhanced the anti-proliferative activity of 5-FU in both *in vitro* and *in vivo* systems (Fig. 6B). Moreover, crocin had an antioxidant activity in homogenized colon samples. Moreover, our data showed that crocin and especially its combination therapy with 5-FU could dramatically reduce the tumor number and tumor size. More specifically, the tumor number was also considerably decreased in both distal and middle parts of the colon. Crocin also ameliorated multiplicity of severe inflammation with mucosal ulcers and high grade dysplastic crypts in mice colon cancer model, which the tumors showed the presence of Polypoid well-differentiated adenocarcinoma and

pedunculated adenocarcinoma with invasion to muscular layer. To further support the protective effect of crocin on colon cancer pathology, we showed that crocin improved colon length, disease activity index (DAI) score, as well as tumor number/colon size ratio. Taken together, our results not only support the importance of crocin as an alternative or adjuvant compound in cancer therapy (Zhang, Wang, Wen, Shoyama & Yuan, 2013), but also are in harmony with the assumption that crocin could improve the 5-FU chemosensitivity.

Consistent with our findings, there are studies showing that the over-activation of the oncogenic PI3K/Akt and Wnt pathways play important roles in cell proliferation, differentiation and migration in CRC (Rahmani, Avan, Hashemy & Hassanian, 2018)(Bahrami et al., 2017b; Jason & Cui, 2016; Song, Li, Liu & Zhao, 2015). Chikazawa et al. reported that silencing of β -catenin, component of Wnt signaling, in CRC cells leads to an elevation in their sensitiveness to paclitaxel and irinotecan (Chikazawa et al., 2010). In agreement with this study, blocking Wnt activity can be considered as a strategy in order to reverse the drug-sensitivity of CD133-positive cells to 5-FU (Deng et al., 2010). In line with this, overexpression of cyclin D1 is well-documented in CRC (Wangefjord, Manjer, Gaber, Nodin, Eberhard & Jirstrom, 2011). In a study on N-nitroso-N-methylurea-induced breast cancer in rats, crocin induced cell cycle arrest via suppression of cyclin D1 (Ashrafi, Bathaie, Abroun & Azizian, 2015). Zhao et al. have also reported the potential activity of crocin in the down-regulation of cyclin D1 in bladder cancer (Zhao, Luo, Wu, Hu, Lv & Ji, 2008). Consistent with these findings, we showed that crocin suppressed cyclin D1 expression in CRC. Thus it can be hypothesized that crocin could increase CRC cells sensitivity to 5-FU via triggering PI3K/Akt and Wnt pathway, as evidenced by down-regulation of p-Akt, p-GSK3 α/β , PI3K and cyclin D1.

Inflammation regulates development of colon carcinogenesis (Campanholo et al., 2015). It has been evidenced that the risk of developing inflammatory bowel disease-associated CRC is highly correlated with the extension and duration of inflammation (Eaden, Abrams & Mayberry, 2001). There are studies supporting the anti-inflammatory activity of crocin (Kawabata, Tung,

Shoyama, Sugie, Mori & Tanaka, 2012). To further investigate the anti-inflammatory effect of crocin, the antioxidant activity of crocin in CRC was analyzed by assessing MDA, CAT and total thiol levels in tissue homogenate samples. Results showed that DSS administration led to a remarkable elevation and reduction in MDA content and CAT activity, respectively. Although the total thiol concentration did not alter significantly in azoxymethane-induced colon cancer rats as compared with control group, but considerable alteration in MDA and CAT levels highlights the involvement of oxidative stress in CRC. Interestingly, crocin and 5-FU combined treatment of azoxymethane-induced colon cancer rats notably recovered the increased levels of MDA and decreased activity of CAT, as well as the decline in total thiol concentration. These data are compatible with the observations of other investigators using saffron and its constituents in order to improve oxidative damage in injury and ischemia in rats (Hosseinizadeh & Younesi, 2002). Increasing evidence showed that oxidative stress plays crucial roles in development and progression of CRC (Babbs, 1990). In particular Chang et al. found that oxidative stress level was increased in CRC subjects (Chang, Wang, Zhao & Pan, 2008). Similarly, several studies have reported that lipid peroxide levels, as an indicator of oxidative stress, are higher in malignant colorectal tissues compared to normal tissue (Ozdemirler Erata, Kanbagli, Durlanik, Bulut, Toker & Uysal, 2005; Ozdemirler, Pabuccuoglu, Bulut, Bugra, Uysal & Toker, 1998). Accordingly, as our result showed that crocin may play an important role in CRC prevention and also therapy by increasing antioxidant levels while decreasing oxidants. These findings suggest that anti-inflammatory responses of crocin plays important role in the chemopreventive functions of crocin in colorectal cancer.

In summary, our results support that crocin may potentiate the therapeutic efficacy of 5-FU in CRC therapy via attenuating cancer cell proliferation and inflammation. These findings, not only suggest that crocin can be considered as a potential anti-cancer compound for CRC treatment, but also could sensitize cancer cells to 5-FU which is at the forefront of drugs in CRC clinical therapy. Although both our *in-vitro* and *in-vivo* investigations successfully brought us to this

conclusion but still further pre-clinical investigations are warranted to explore this therapeutic combination as well as its detailed antitumor mechanisms.

Acknowledgment:

This research was partly supported by grants awarded by the Mashhad University of Medical Sciences, grant No. 960692 (Amir Avan), National Institute for Medical research Development, grant No. 958349 and TWAS-UNESCO No. 17-094 RG/PHA/AS_C – FR3240300063.

References

Aebi H (1984). [13] Catalase in vitro. *Methods in enzymology* 105: 121-126.

Almagami AA, Alshawsh MA, Saif-Ali R, Shwter A, Salem SD, & Abdulla MA (2014). Evaluation of chemopreventive effects of *Acanthus ilicifolius* against azoxymethane-induced aberrant Crypt Foci in the rat colon. *PLoS one* 9: e96004.

Amin A, Hamza AA, Bajbouj K, Ashraf SS, & Daoud S (2011). Saffron: a potential candidate for a novel anticancer drug against hepatocellular carcinoma. *Hepatology* 54: 857-867.

Amin A, Hamza AA, Daoud S, Khazanehdari K, Hroust AA, Baig B, *et al.* (2016). Saffron-Based Crocin Prevents Early Lesions of Liver Cancer: In vivo, In vitro and Network Analyses. *Recent patents on anti-cancer drug discovery* 11: 121-133.

Anto RJ, Mukhopadhyay A, Denning K, & Aggarwal BB (2002). Curcumin (diferuloylmethane) induces apoptosis through activation of caspase-8, BID cleavage and cytochrome c release: its suppression by ectopic expression of Bcl-2 and Bcl-xl. *Carcinogenesis* 23: 143-150.

Ashrafi M, Bathaie SZ, Abroun S, & Azizian M (2015). Effect of Crocin on Cell Cycle Regulators in N-Nitroso-N-Methylurea-Induced Breast Cancer in Rats. *DNA and cell biology* 34: 684-691.

Aung HH, Wang CZ, Ni M, Fishbein A, Mehendale SR, Xie JT, *et al.* (2007). Crocin from *Crocus sativus* possesses significant anti-proliferation effects on human colorectal cancer cells. *Experimental oncology* 29: 175-180.

Avan A, Avan A, Le Large TY, Mambrini A, Funel N, Maftouh M, *et al.* (2014). AKT1 and SELP polymorphisms predict the risk of developing cachexia in pancreatic cancer patients. *PLoS one* 9: e108057.

Avan A, Caretti V, Funel N, Galvani E, Maftouh M, Honeywell RJ, *et al.* (2013a). Crizotinib inhibits metabolic inactivation of gemcitabine in c-Met-driven pancreatic carcinoma. *Cancer research* 73: 6745-6756.

Avan A, Crea F, Paolicchi E, Funel N, Galvani E, Marquez VE, *et al.* (2012). Molecular mechanisms involved in the synergistic interaction of the EZH2 inhibitor 3-deazaneplanocin A with gemcitabine in pancreatic cancer cells. *Molecular cancer therapeutics* 11: 1735-1746.

Avan A, Quint K, Nicolini F, Funel N, Frampton AE, Maftouh M, *et al.* (2013b). Enhancement of the antiproliferative activity of gemcitabine by modulation of c-Met pathway in pancreatic cancer. *Current pharmaceutical design* 19: 940-950.

Babbs CF (1990). Free radicals and the etiology of colon cancer. *Free radical biology & medicine* 8: 191-200.

Bahrami A, Amerizadeh F, Hassanian SM, ShahidSales S, Khazaei M, Maftouh M, *et al.* (2017a). Genetic variants as potential predictive biomarkers in advanced colorectal cancer patients treated with oxaliplatin-based chemotherapy. *Journal of cellular physiology*.

Bahrami A, Amerizadeh F, ShahidSales S, Khazaei M, Ghayour-Mobarhan M, Sadeghnia HR, *et al.* (2017b). Therapeutic Potential of Targeting Wnt/beta-catenin Pathway in Treatment of Colorectal Cancer: Rational and Progress. *Journal of cellular biochemistry*.

Bahrami A, Khazaei M, Bagherieh F, Ghayour-Mobarhan M, Maftouh M, Hassanian SM, *et al.* (2017c). Targeted Stroma in Pancreatic Cancer: Promises and Failures of Target Therapies. *Journal of cellular physiology*.

Bahrami A, Shahidsales S, Khazaei M, Ghayour-Mobarhan M, Maftouh M, Hassanian SM, *et al.* (2017d). C-Met as a Potential Target for the Treatment of Gastrointestinal Cancer: Current Status and Future Perspectives. *Journal of cellular physiology*.

Bathaie SZ, Hoshyar R, Miri H, & Sadeghizadeh M (2013). Anticancer effects of crocetin in both human adenocarcinoma gastric cancer cells and rat model of gastric cancer. *Biochemistry and cell biology = Biochimie et biologie cellulaire* 91: 397-403.

Bathaie SZ, Miri H, Mohagheghi MA, Mokhtari-Dizaji M, Shahbazfar AA, & Hasanzadeh H (2013). Saffron Aqueous Extract Inhibits the Chemically-induced Gastric Cancer Progression in the Wistar Albino Rat. *Iranian journal of basic medical sciences* 16: 27-38.

Campanholo VM, Silva RM, Silva TD, Neto RA, Paiotti AP, Ribeiro DA, *et al.* (2015). Oral concentrated grape juice suppresses expression of NF-kappa B, TNF-alpha and iNOS in experimentally induced colorectal carcinogenesis in Wistar rats. *Asian Pacific journal of cancer prevention : APJCP* 16: 947-952.

Chang D, Wang F, Zhao YS, & Pan HZ (2008). Evaluation of oxidative stress in colorectal cancer patients. *Biomedical and environmental sciences : BES* 21: 286-289.

Chikazawa N, Tanaka H, Tasaka T, Nakamura M, Tanaka M, Onishi H, *et al.* (2010). Inhibition of Wnt signaling pathway decreases chemotherapy-resistant side-population colon cancer cells. *Anticancer research* 30: 2041-2048.

Chryssanthi DG, Dedes PG, Karamanos NK, Cordopatis P, & Lamari FN (2011). Crocetin inhibits invasiveness of MDA-MB-231 breast cancer cells via downregulation of matrix metalloproteinases. *Planta medica* 77: 146-151.

D'Alessandro AM, Mancini A, Lizzi AR, De Simone A, Marroccella CE, Gravina GL, *et al.* (2013). Crocus sativus stigma extract and its major constituent crocin possess significant antiproliferative properties against human prostate cancer. *Nutrition and cancer* 65: 930-942.

Deng YH, Pu XX, Huang MJ, Xiao J, Zhou JM, Lin TY, *et al.* (2010). 5-Fluorouracil upregulates the activity of Wnt signaling pathway in CD133-positive colon cancer stem-like cells. *Chinese journal of cancer* 29: 810-815.

Dhar A, Mehta S, Dhar G, Dhar K, Banerjee S, Van Veldhuizen P, *et al.* (2009). Crocetin inhibits pancreatic cancer cell proliferation and tumor progression in a xenograft mouse model. *Molecular cancer therapeutics* 8: 315-323.

Eaden JA, Abrams KR, & Mayberry JF (2001). The risk of colorectal cancer in ulcerative colitis: a meta-analysis. *Gut* 48: 526-535.

Garcia-Olmo DC, Riese HH, Escribano J, Ontanon J, Fernandez JA, Atienzar M, *et al.* (1999). Effects of long-term treatment of colon adenocarcinoma with crocin, a carotenoid from saffron (*Crocus sativus* L.): an experimental study in the rat. *Nutrition and cancer* 35: 120-126.

Hammond WA, Swaika A, & Mody K (2016). Pharmacologic resistance in colorectal cancer: a review. *Therapeutic advances in medical oncology* 8: 57-84.

Hashemzahi M, Behnam-Rassouli R, Hassanian SM, Moradi-Binabaj M, Moradi-Marjaneh R, Rahmani F, Fiuji H, Jamili M, Mirahmadi M, Boromand N, Piran M, Jafari M, Sahebkar A, Avan A, Khazaei M. Phytosomal-curcumin antagonizes cell growth and migration, induced by thrombin through AMP-Kinase in breast cancer. *J Cell Biochem.* 2018;119(7):5996-6007

Hoshyar R, Bathaie SZ, & Sadeghizadeh M (2013). Crocin triggers the apoptosis through increasing the Bax/Bcl-2 ratio and caspase activation in human gastric adenocarcinoma, AGS, cells. *DNA and cell biology* 32: 50-57.

Hosseinzadeh H (2014). Saffron: a herbal medicine of third millennium. *Jundishapur journal of natural pharmaceutical products* 9: 1-2.

Hosseinzadeh H, & Sadeghnia HR (2005). Safranal, a constituent of *Crocus sativus* (saffron), attenuated cerebral ischemia induced oxidative damage in rat hippocampus. *J Pharm Pharm Sci* 8: 394-399.

Hosseinzadeh H, & Younesi HM (2002). Antinociceptive and anti-inflammatory effects of *Crocus sativus* L. stigma and petal extracts in mice. *BMC pharmacology* 2: 7.

Jason S, & Cui W (2016). Proliferation, survival and metabolism: the role of PI3K/AKT/mTOR signalling in pluripotency and cell fate determination. *Development* 143: 3050-3060.

Kawabata K, Tung NH, Shoyama Y, Sugie S, Mori T, & Tanaka T (2012). Dietary Crocin Inhibits Colitis and Colitis-Associated Colorectal Carcinogenesis in Male ICR Mice. *Evidence-based complementary and alternative medicine : eCAM* 2012: 820415.

Longley DB, Allen WL, & Johnston PG (2006). Drug resistance, predictive markers and pharmacogenomics in colorectal cancer. *Biochimica et biophysica acta* 1766: 184-196.

Maftouh M, Avan A, Funel N, Frampton AE, Fiuji H, Pelliccioni S, *et al.* (2014a). miR-211 modulates gemcitabine activity through downregulation of ribonucleotide reductase and inhibits the invasive behavior of pancreatic cancer cells. *Nucleosides, nucleotides & nucleic acids* 33: 384-393.

Maftouh M, Avan A, Sciarrillo R, Granchi C, Leon LG, Rani R, *et al.* (2014b). Synergistic interaction of novel lactate dehydrogenase inhibitors with gemcitabine against pancreatic cancer cells in hypoxia. *British journal of cancer* 110: 172-182.

Maftouh M, Belo AI, Avan A, Funel N, Peters GJ, Giovannetti E, *et al.* (2014c). Galectin-4 expression is associated with reduced lymph node metastasis and modulation of Wnt/beta-catenin signalling in pancreatic adenocarcinoma. *Oncotarget* 5: 5335-5349.

Marjaneh RM, Rahmani F, Hassanian SM, Rezaei N, Hashemzahi M, Bahrami A, *et al.* (2018). Phytosomal curcumin inhibits tumor growth in colitis-associated colorectal cancer. *Journal of cellular physiology*.

Michl P, & Downward J (2005). Mechanisms of disease: PI3K/AKT signaling in gastrointestinal cancers. *Zeitschrift fur Gastroenterologie* 43: 1133-1139.

Nedaeinia R, Sharifi M, Avan A, Kazemi M, Rafiee L, Ghayour-Mobarhan M, *et al.* (2016). Locked nucleic acid anti-miR-21 inhibits cell growth and invasive behaviors of a colorectal adenocarcinoma cell line: LNA-anti-miR as a novel approach. *Cancer gene therapy* 23: 246-253.

Ozdemirler Erata G, Kanbagli O, Durlanik O, Bulut T, Toker G, & Uysal M (2005). Induced oxidative stress and decreased expression of inducible heat shock protein 70 (ihsp 70) in patients with colorectal adenocarcinomas. *Japanese journal of clinical oncology* 35: 74-78.

Ozdemirler G, Pabuccuoglu H, Bulut T, Bugra D, Uysal M, & Toker G (1998). Increased lipoperoxide levels and antioxidant system in colorectal cancer. *Journal of cancer research and clinical oncology* 124: 555-559.

Rahmani F, Avan A, Hashemy SI, & Hassanian SM (2018). Role of Wnt/beta-catenin signaling regulatory microRNAs in the pathogenesis of colorectal cancer. *J Cell Physiol* 233: 811-817.

Rovithi M, Avan A, Funel N, Leon LG, Gomez VE, Wurdinger T, *et al.* (2017). Development of bioluminescent chick chorioallantoic membrane (CAM) models for primary pancreatic cancer cells: a platform for drug testing. *Scientific reports* 7: 44686.

Siegel RL, Miller KD, & Jemal A (2016). Cancer statistics, 2016. *CA: a cancer journal for clinicians* 66: 7-30.

Song L, Li ZY, Liu WP, & Zhao MR (2015). Crosstalk between Wnt/beta-catenin and Hedgehog/Gli signaling pathways in colon cancer and implications for therapy. *Cancer biology & therapy* 16: 1-7.

Sugie S, Suzuki R, Tanaka T, & Kohno H (2005). Dose-dependent promoting effect of dextran sodium sulfate on mouse colon carcinogenesis initiated with azoxymethane. *Histology and histopathology*.

Vadlakonda L, Pasupuleti M, & Reddanna P (2013). Role of PI3K-AKT-mTOR and Wnt signaling pathways in transition of G1-S phase of cell cycle in cancer cells. *Frontiers in oncology* 3: 85.

Wangefjord S, Manjer J, Gaber A, Nodin B, Eberhard J, & Jirstrom K (2011). Cyclin D1 expression in colorectal cancer is a favorable prognostic factor in men but not in women in a prospective, population-based cohort study. *Biology of sex differences* 2: 10.

Zhang N, Yin Y, Xu SJ, & Chen WS (2008). 5-Fluorouracil: mechanisms of resistance and reversal strategies. *Molecules* 13: 1551-1569.

Zhang Z, Wang CZ, Wen XD, Shoyama Y, & Yuan CS (2013). Role of saffron and its constituents on cancer chemoprevention. *Pharmaceutical biology* 51: 920-924.

Zhao P, Luo CL, Wu XH, Hu HB, Lv CF, & Ji HY (2008). [Proliferation apoptotic influence of crocin on human bladder cancer T24 cell line]. *Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica* 33: 1869-1873.

Figures legends

Figure 1. Crocin inhibits cell proliferation and invasion of colon cancer cells. (A) Growth inhibitory effects of crocin (μM) after 72 hours exposure to crocin in CT-26 cells. (B) Mean combination index (CI) of the crocin/5-FU treatment. CI values at fractional effect analysis (FA) of 0.5, 0.75 and 0.9 were averaged for each experiment, and this value was used to calculate the mean between experiments. (C) Effect of crocin on the CRC spheroids (D) Results of invasion experiment in the CRC cells exposed to crocin at IC_{50} values for 24 hours. (E) Modulation of E-cadherin, MMP-2 and MMP-9 mRNA levels in CRC cells after 24 hours exposure to crocin (3 mM) as determined by q-RT-PCR. (F) The inhibitory effect of crocin on the migration of CT-26 cells. Columns or Points, mean values obtained from three independent experiments; bars, SEM. *Significantly different from controls.

Figure 2. Cell cycle distribution of the colon cancer cells upon crocin treatment.

CT-26 cells were treated with two concentrations of crocin (3 mM and 5 mM) for 24 hr and after staining with propidium iodide (PI), analyzed by flow cytometry for cell cycle and sub G1 analysis (A-D, respectively).

Figure 3. Crocin suppresses tumor growth in a mouse model of colitis-associated colorectal cancer. (A) The treatment schedules and development of colitis-associated colorectal cancer models. Mice were given 10 mg/kg body weight AOM. One week after AOM injection, they received 1.5% DSS/oral-gavage for 7 days, followed by 2 weeks rest. One week after DSS exposure groups 3, 4, and 5 were treated with crocin, 5-FU, crocin + 5-FU for 15 weeks, respectively; (B) Colitis-associated colorectal cancer mice were treated with different reagents as indicated and number of tumors were analyzed in each group., (C) The same as B, except that tumor size was analyzed. (D) The same as B, except that tumor location was analyzed in each group. (E) Colitis-associated colorectal cancer mice were treated as explained in B and tumor area was analyzed. (F) The same as B, except that colon length was analyzed. (G) Picture of colons, indicating tumors in 4 groups, AOM/DSS, 5-FU, crocin and 5-FU+crocin. Columns or Points, mean values obtained from three independent experiments; bars, SEM. *Significantly different from controls.

Figure 4. Crocin regulates oxidative stress in homogenized colon samples. Mice were treated ad indicated and following collection of colon samples. MDA (A), catalase (B), total thiol concentration (C) and SOD activity (D) were measured in colon tissues. Columns or Points, mean values obtained from three independent experiments; bars, SEM. *Significantly different from controls.

Figure 5. Crocin ameliorates multiplicity of severe inflammation with mucosal ulcers and high grade dysplastic crypts. A and a) tissue from group 1 (mice without AZO/DSS treatment); B-C, b-c) tissue from group 2 (mice with AZO/DSS treatment), Polypoid well-differentiated adenocarcinoma (black arrows) and pedunculated adenocarcinoma (red arrows)

with invasion to muscular layer (white arrow); In situ adenocarcinoma (black arrows) and tubular adenoma/adenocarcinoma (red arrows); D-F, d-f) effect of crocin, 5-FU and crocin+5-FU on colon; G) total inflammation score; H) Crypt loss score; I) Pathological changes score; J) Histology score; Columns or Points, mean values obtained from three independent experiments; bars, SEM. *Significantly different from controls. K-N) a representative picture of inflammation with respect to effect of crocin, 5-FU and crocin+5-FU. The H&E stained histopathological examination illustrated that there were no pathological changes in ventricular muscle structure in the control group (A,a). In contrast, in LPS group, increased infiltration of inflammatory cells and disarrangement of myofibers were observed (B-C, b-c). Administration of crocin and its combination with 5-FU illustrated improvement of pathological changes).

Figure 6. Schematic representation of the molecular mechanisms involved in the synergistic effects of crocin on 5-FU. A-B) Modulation of CyclinD1 and surviving at mRNA levels and PI3K, Cyclin D1, P-Akt and p-GSK3 α/β at protein level in CRC cells after 24 hours exposure to crocin (3 mM) as determined by q-RT-PCR and Western blot. Columns mean values obtained from three independent experiments; bars, SEM. *Significantly different from controls.C) Crocin inhibits PI3K/Akt and Wnt activation and enhances the growth inhibitory effects of 5-FU through its pronounced anti-proliferative and anti-invasive effects, as well as the attenuation of inflammation and oxidative stress status.





Figure 1






Figure 2




Figure 3




Figure 4




Figure 5